This is an excellent overview of what happened in the field of psychedelics in 2021 with an additional look ahead to what is likely to emerge in 2022.

Low doses of LSD are safe, but produce negligible changes in mood or cognition in healthy volunteers.

LSD changed creativity across modalities and measurement approaches.

Consuming small doses of psilocybin at regular intervals — a process known as microdosing — does not appear to improve symptoms of depression or anxiety

Our review shows that medical risks are often minimal, and that many – albeit not all – of the persistent negative perceptions of psychological risks are unsupported.

Researchers in the field of psychedelics hit the ground running at the turn of the new year.

2022 looks set to be another busy year for the psychedelics space, with a number of late-stage clinical trials commencing or wrapping

What credentials will likely be necessary to legally provide psychedelic therapy?

The purpose of this Primer is to provide those interested in the field of psychedelics with a concise and accessible overview of the scientific data.

Symptom reduction following ketamine infusions in severely ill patients suggest that ketamine, despite being inferior to ECT, can be a safe and valuable tool .

The Innovative Licensing and Access Pathway (ILAP) Innovation Passport has ben granted to MDMA as an adjunct to therapy for posttraumatic stress disorder (PTSD) in the United Kingdom (UK).

This review examines the positive and negative aspects of different formulations and routes of administration of DMT

Development of meaning-creating psychotherapies and further research findings in psychedelic therapies may contribute to more compassionate and mindful care.

Suicide is a global health concern, and innovative interventions that target suicidality are needed.

The present research aimed to uncover an emerging model of MDMA use grounded in the experiences of adult couples using MDMA privately and in the context of their committed relationships.

This study compared five psychedelic substance report groups and a non-psychedelic report group on quantitative linguistic markers.

Exactly fifty years after the ban on psychedelics a group of Zen meditators – who have never used any psychedelic substances before – are given psilocybin on the last day of a 5-day retreat. Half the group receives a placebo.

There are neurophysiological and phenomenological overlaps between psychedelic and meditative states, but there is little evidence on how exposure to psychedelics might be associated with meditation-related variables. We assessed lifetime classic psychedelic use, ego dissolution during one's most intense experience using a classic psychedelic, and exposure to meditation in a representative sample (n = 953) of American adults.

The resurgence of research into psychedelics has continued to thrive over the past year. Dozens of trials and hundreds of studies have been published in 2021.

Ketamine treatment was well tolerated and was also helpful.